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Abstract: 
Background: Results of a trial of prenatal Vitamin D supplementation are analyzed for 
associations of pill count data with serum-based measures of adherence. 
Objective: It is hypothesized that adherence as measured by pill count will have a 
significant association with serum-based measures of adherence. 
Design: The study from which the data for this analysis were derived is a large 
randomized, controlled, and double-blinded trial of vitamin D supplements in pregnant 
women. The women have been stratified by race and randomized into three groups, 
which receive a 400lU (control), 2000lU, or 4000lU dose of vitamin D3 once daily. 
Women enter the study at or before 12 weeks gestation and continue their 
supplementation throughout pregnancy and the first year postpartum. 
Results: A series of 5 multivariate logistic regression models was created to examine 
whether mean percent adherence by pill count was significantly associated with the 
thresholds of adherence by serum 2S(OH)D when controlling for race, dose, age, season 
at enrollment, and initial BMI. The analysis revealed that mean percentage of 
adherence by pill count was not a significant predictor of adherence by serum 2S-0HD 
at any time point. Odds ratios ranged from 0.9 to 1.1, and a significance level of 0.05 
was not reached at any time point 
Conclusions: In a multivariate logistic regression, there was not a significant association 
between adherence as defined by serum and mean percent pill count adherence for any 
time point. 
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Chapter I - Introduction: 
Vitamin D is an important nutrient that is widely known to be vital to bone 
health and development, although it has recently been linked to other systems such as 
immune function{l}. The two main human sources of vitamin D are sunlight exposure, 
which converts 7-dehydrocholesterol in the skin to vitamin D3, and oral intake. Due to 
the limited dietary sources of vitamin D, serum vitamin D levels are primarily 
determined by sunlight exposure. The amount of vitamin D produced by a given 
amount of exposure is modified by skin pigmentation, with darkly-pigmented 
populations producing significantly less vitamin D than fair-skinned populations after 
exposure to similar conditions (2). 
Existing gUidelines recommend that pregnant women receive 200lU of vitamin D 
per day via an oral supplement (3). However, among African-American women who 
take daily supplementation in twice this amount, the rate of hYPovitaminosis D is still 
28% (4). The incidence of rickets, a pathology which can develop among children with 
hypovitaminosis D, is increasing, especially among darkly-pigmented populations (5-7), 
Studies are currently underway to determine the optimum supplementation dose of 
vitamin D among pregnant women (Wagner, Hollis, in progress). Once the optimum 
dose is determined, the treatment effect of this intervention will be modified by the 
level of nonadherence among the patient population. The clinical implications of 
nonadherence are numerous and well-recognized (8). 
Adherence to study medication is most often measured by a calculation of pill 
count. This is an inexpensive measure of compliance, but the data is unreliable and 
often missing. For example, in a 2005 study of prenatal supplements 56% of subjects 
remembered to return only one monthly pill bottle during the duration of the 2-3 month 
study (9). With this method, researchers are not only depending on patients to return 
bottles, but not to alter the number of remaining doses as well. In a 2001 study of 
protease inhibitor regimen adherence among HIV patients, pill count measures 
estimated adherence at 83%, but electronic monitors on the pill bottles revealed that 
true adher~nce was only 63% (10). 
Lack of adherence dilutes treatment effects, which impacts the health of the 
target population. The purpose of this study was to define parameters for measuring 
adherence to vitamin D supplementation by serum metabolite levels in order to 
examine the association between adherence as determined by serum metabolites and 
adherence as determined by patients' pill counts. 
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Chapter 2 .. Literature Review 
Patient Adherence and Prenatal Vitamin D supplementation 
Thesis Document: Analyzing adherence to prenatal supplements: 
Introduction: 
Does pHi count measure up? 
Advisory Committee: 
Paul Nietert, PhD 
Carol Wagner, MD 
Thomas Hulsey, ScD 
Bruce Hollis, MD PhD 
June 2008 
This literature review encompasses two principal domains, patient adherence to 
prescribed medication regimens and the specific need for adherence to prenatal vitamin 
D supplementation. The thesis document which it supports is a study of measures of 
patient adherence in the context of a research project to determine appropriate 
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prenatal vitamin 0 supplementation dosage. Therefore/ it is important not only to 
review known information on patient adherence in general, but also its specific 
importance in the clinical context of prenatal care. 
Background: 
Measures of patient adherence 
One of the problems in researching any treatment is that of patient adherence to 
a prescribed regimen. How can one accurately measure the effect of an intervention if 
one is not certain that the patient is completing the treatment in the manner 
prescribed? In effect, this will dilute the true treatment effect and could also 
underestimate potential side effects of the dose studied. Also, it is difficult to take a 
lack of adherence into consideration in data analysis if one does not have a reliable 
measure of the prevalence and degree of these deviations from the intended 
intervention. 
Lack of adherence is an important problem in the clinical realm as well (8). If an 
intervention is not having the desired effect, it is important for the clinician to know 
whether to attribute this lack of effectiveness to a lack of efficacy of the agent in a 
particular patient or simply patient non-adherence. If the clinician cannot adequately 
assess adherence, he or she may switch the patient to a new intervention with, for 
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example, more prominent side effects, when all that was needed was to reinforce the 
importance of taking the medication exactly as prescribed. 
A previous review of literature on patient adherence found estimates of regimen 
adherence ranging from 19% to 100% (11). This could be due in part to the variety of 
methods and standards used. When considering adherence, it is important to keep in 
mind that it is not a homogeneous phenomenon. There are those subjects who never 
start the prescribed regimen, those who discontinue treatment prematurelYI and those 
who continue treatment throughout the required time period but deviate from the 
prescribed regimen. This last group can be further subdivided into three overlapping 
categories. These include subjects that skip doses, subjects that do not take the 
regimen at the intended time intervals, and even those who take too many doses. The 
diversity of the phenomenon known as non-adherence makes the task of measuring it 
more difficult, as a single method could address some aspects of the issue but not 
others. 
Many tools have been used to attempt to measure the lack of adherence in a 
patient population} each of which exhibits both strengths and weaknesses. We will 
undertake a review of recent and relevant literature in this arena. 
In general, existing methods of determining adherence fall into the categories of 
indirect and direct measures. We will begin our review with indirect measures, 
including self-report, pill count, and pharmacy data. More direct and objective 
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measures reviewed will include medication event monitoring systems (MEMS), serum 
assays, and direct patient observation. 
Indirect Assessment of Adherence: 
Self-report 
Self report is really a category for diverse forms of measurement, all of which are 
generally quite inexpensive and easy to use. This can be done via patient diary, 
interview, or a specifically-designed questionnaire. Among techniques, one specific 
interview question set yielded accuracy of about 75% (12); however, in this study the 
gold standard used for comparison was pill count, the flaws of which are discussed 
below. In addition, a 1998 article found that in an elderly population on long-term 
medications for chronic conditions, self-report and pharmacy claim data led to a higher 
estimation of adherence when compared to pill count (13). 
The self-administered Basic Medication Questionnaire is another option; it 
includes not only questions about adherence, but also sections that focus on patient 
beliefs about the usefulness of the medication, potential adverse effects, and whether 
the subject is having trouble recollecting facts related to his or her level of adherence. 
The different domains of the BMQ showed an accuracy of 40-95% when results were 
compared to medication event monitoring system (MEMS) data, which was used as the 
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gold standard in this study (14). MEMS is a modern, electronic adherence assessment 
system which will be discussed separately later in this review. 
A 2004 meta-analysis further analyzed self-report. In this case, all self-report 
data was compared to electronic monitoring as the gold standard. The concordance 
between the two types of measures was high in only 17% of cases (15). This meta-
analysis also revealed another important finding. Interviews were much less likely to be 
concordant with electronic monitoring data when compared to other self-report 
formats, such as questionnaires and subject diaries. No studies included in the analysis 
showed a high concordance between interview results and electronic monitoring data, 
while data from questionnaires and subject diaries were highly concordant with the 
MEMS data in almost a third of the 16 such studies analyzed (15). 
The advantages of patient diary and interview techniques are that they allow for 
assessment of a variety of forms of adherence. They not only measure whether the 
subject started and maintained the treatment, but can also assess missed doses, extra 
doses, and whether the subject kept to the intended schedule outlined in the prescribed 
regimen. Disadvantages of self-report techniques are lack of accurate records, inability 
to remember specific adherence behaviors, and possible fabrication of responses. 
Pill Count 
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Pill count is an inexpensive but potentially unreliable way of measuring 
adherence. Due to its low cost and ease of calculation, this measure has been frequently 
used in the literature. There are many potential pitfalls to this method, including the 
important problem of missing data. For example, in a 2005 study of prenatal 
supplements 56% of subjects only remembered to return one of their monthly pill 
bottles during the 2-3 month duration of the study (9). With this method, researchers 
are not only depending on patients to return bottles, but to refrain from altering the 
number of remaining doses. This can be problematic, and often leads to overestimation 
of adherence. For example, in a 2001 study of protease inhibitor compliance among HIV 
patients, pill count measures put adherence at 83% while MEMS data showed a 63% 
adherence rate (10). 
Another problem with measuring adherence by pill count is that cut-offs for 
adherence are relatively arbitrary. Frequently, adherence in a single patient is 
measured by the percent of expected doses that were taken over a given time interval. 
This is calculated by the following formula: 
(# of pills dispensed - # of pills returned) / (# of elapsed dosing periods between 
dispense date and return date) 
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Many studies then convert this figure into a dichotomous variable, classifying 
patients as adherent or non-adherent based upon whether the calculated percentage 
falls above or below a pre-established standard. This cut-off for pill count adherence 
varies between studies. It is understandable that some conditions may require greater 
medication adherence than others, due to short half-lives of medications or the severity 
less specificity, while a lower threshold would confer more less sensitivity but more 
specificity (11). 
Measuring adherence by pill count has the previously mentioned advantages of 
low cost and ease of calculation, but it has disadvantages as well. Besides missing data, 
arbitrary cut-offs, and possible alterations by subjects, pill count data also do not detect 
all types of non-adherence. Pill count data would detect those patients who never 
began treatment, those who discontinued treatment, and those who skipped doses, but 
it offers no information on other aspects of non-adherence. For instance, pill count data 
cannot be used to assess whether a subject took the medication on the intended 
schedule. Also, many studies that measure adherence by pill count have no provisions 
for patients who took too many doses; this is also an important aspect of non-
adherence, since overdose and dependence are important risks to many medications. 
9 
Pharmacy Data 
Researchers seeking an alternative measure of adherence have analyzed 
pharmacy records to infer patient behavior based on the intervals at which refills were 
obtained. As with many of the other methods discussed in this review, the measures of 
refill compliance varied between studies. Refill compliance could be described as a 
continuous or dichotomous variable, much like pill count. It could also be measured 
over a single time point or over multiple time intervals. Finally, some analyses of refill 
compliance examine the time period when the medication was available, while others 
focus on the gaps in therapy inferred from pharmacy data (16). 
The accuracy of pharmacy refill data is generally well-correlated with more direct 
measures of adherence. A review of pharmacy refill adherence studies showed that 3 
out of 3 studies analyzed showed a significant association between refill data and 
subject serum drug levels, while 4 out of 5 studies showed a statistically significant 
association between refills and the anticipated effect of the medication (16). 
As with other methods, pharmacy data has both advantages and disadvantages 
in measuring adherence. Strengths of this method include its relative lack of 
invasiveness; patients need only give their permission for these records to be accessed, 
and are not required to fill out forms, sit for interviews, or undergo venopuncture. It 
also has low cost and is easier than other methods to apply to a large population, which 
may be helpful in fields such as health services research. However it has disadvantages 
as well. Patients may refill their prescription at the assigned time even though they 
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have not taken all of the required doses. This is even more likely in recent years, as 
automatic refills and pharmacies-by-mail have become more common. Also, refill data 
do not offer any information on whether doses were taken according to the prescribed 
schedule. A final weakness of this method is that many patients refill before the 
assigned time interval has expired. Steiner and Prochazka found that different studies 
placed the prevalence of medication stockpiling between 4.8% and 35.1%. In this case, 
it is impossible to determine if the patient is consuming more than the prescribed dose, 
sharing doses with others, or simply hoarding the medication unless researchers follow-
up with another inquiry method, such as interview. 
Direct Assessment of Adherence: 
Electronic Monitoring 
Medication Event Monitoring Systems (MEMS) are a type of electronic 
monitoring of medication usage that functions by recording electronically the time and 
date that a pill bottle is opened, an inhaler is used, or a dropper dispensed. They 
represent a large expense for a study, but also provide specific information on the exact 
pattern of medication usage. The data obtained can reveal large discrepancies from that 
provided by self-report. For example, one 2007 study of schizophrenic patients (10) 
showed that the rate of subject non-adherence (defined as a dichotomous variable with 
an 80% adherence threshold) according to self report was only 3%, while MEMS data 
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revealed that the actual rate was 52%. This is an extreme example, likely affected by 
both the small number of patients (n= 52) and the strong association of their pathology 
with paranoia and disorganized cognition. However, effects in other populations are 
also significant. Another study demonstrated that comparison to electronic monitoring 
data demonstrated that 30% of entries in patient-kept regimen adherence diaries were 
in error (17). 
One of the more remarkable results from studies in which electronic monitoring 
devices were used was the confirmation of the phenomenon of "white coat 
compliance," the desire to appear adherent at study visits. Subjects in one study were 
told that their inhalers were going to be weighed at visits to assess adherence, but were 
unaware that the dosing meter contained a chronolog that recorded the time and data 
of device actuations. 14% of subjects actuated the inhaler over 100 times in the three 
hours previous to a study visit, detecting deliberate medication dumping (18). 
As an adherence assessment method, MEMS data are useful because, unlike 
many other measures, they allow the researcher to access information on whether the 
medication was taken on the prescribed schedule. It has been used as the gold standard 
of patient adherence measures in recent years due to the wealth of data provided by 
the monitoring devices. One of the weaknesses of this method is that it does not 
account for specific circumstances, such as two people in a household taking the same 
medication or a subject who dispenses all doses into a pill-case at the beginning of the 
week. Another disadvantage is that, while MEMS devices do offer objective data, they 
12 
do not prove that a dose was actually consumed each time that the bottle was opened, 
the inhaler actuated, and so on. Finally, electronic monitoring devices are costly. While 
they are feasible in the context of well-funded studies, MEMS devices are impractical for 
inclusion in many research budgets. The cost is prohibitive, which means that the use of 
electronic monitoring is limited to research, and not practical for the clinical context in 
most cases. 
Serum Assays 
Direct measures such as blood and serum assays are another objective way to 
measure patient adherence. Three types of serum measures are commonly used for 
this purpose: biologic markers with known half~lives added to medications, metabolites 
of medications and supplements, and levels of the medication in the serum. When 
using this method of assessment, it is important to consider that some compounds 
could also be obtained from other sources, such as dietary intake affecting caffeine 
levels, or, in the case of vitamin D supplementation, even exposure to sunlight. In the 
analysis, these other exposures that could affect serum levels of the compound of 
interest must be taken into account. Options to accomplish this include stratification by 
such possible confounders or adjustment for known exposures in the analysis. 
Another key consideration in the use of serum levels as indicators of patient 
adherence is the half-life of the compound in question. Those compounds with a short 
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half-life lend themselves to an analysis of short-term adherence. While this is one 
indicator, one must keep in mind the phenomenon of "white coat compliance" 
discussed earlier. Compounds with longer half-lives can be used to assess long- or 
intermediate-term adherence. This gives a clearer picture of consistency of adherence 
than a short half-life compound. In considering the above concept, one can imagine a 
clinician who would like to track the adherence of his or her patient to their diabetes 
treatment. While the blood glucose reading taken that day gives a measure of current 
glucose control, a laboratory measurement of serum HbA1C measures the consistency 
of blood glucose control over a two or three month period (19). 
Strengths of serum assays to determine adherence include their objectivity and 
usual predictability. The main difficulty is determining the appropriate cut-off point to 
use as the standard of adherence in a given population. Confounding factors such as 
age, gender, and BMI can influence serum concentrations of a metabolite (20-22). In 
addition, genetic polymorphisms could affect the rate at which metabolites are 
produced or cleared from the circulation. An extreme example is a population with 
ALDH2*2 alleles. In such a population, which includes about half of Chinese, Japanese, 
and Korean persons, one would make erroneous assumptions if attempting to estimate 
the amount of alcohol consumed by the level of acetaldehyde in each subject's serum 
(23). This is because this specific genetic polymorphism results in a deficiency in 
aldehyde dehydrogenase, the enzyme which converts the toxic ethanol metabolite 
acetaldehyde to acetic acid. 
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Direct Observation 
Due to the weaknesses of the methods described above, direct observation is 
the only true way to assess all of the different possible permutations of patient non-
adherence. Of course, this assessment method is very costly and labor-intensive, which 
usually limits its use to the inpatient setting. However, this method has also been used 
in other contexts. In a 2005 analysis of the effectiveness of Echinacea to prevent and 
ameliorate cold symptoms, subjects were sequestered in individual hotel rooms during 
a five day period (24). In this study, a method of liquid measurement which can be 
approximated to pill count had been used to measure adherence during an outpatient 
period. The authors noted that although the adherence was evaluated to be very good 
during the outpatient period, they were only certain of the adherence in the isolation 
phase, when direct observation was used at the time of each dose. 
Importance of Vitamin 0 Supplementation 
Vitamin D is an important nutrient that is widely known to be vital to bone 
health and development, although it has recently been linked to other systems such as 
immune function (1). Recently there has been a wealth of research into the beneficial 
effects of vitamin D. As one example, a new study shows that even after adjusting for 
other known risk factors, men who are deficient in 25-0H D are significantly more likely 
to suffer a myocardial infarction when compared to men with a 25-0H D serum 
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measurement that classifies as sufficient (25). Another new study, which examined data 
from 51 regions around the world, found a significant association between a low level of 
sun exposure and a high incidence rate of type 1 diabetes in children after controlling 
for per capita health expenditure in each country studied (26). 
Vitamin D status is particularly important during fetal development and infancy. 
Previously established roles of adequate vitamin D in infants and children, particularly, 
were the integrity of bone development and prevention of rickets, a softening of the 
bones caused by inadequate vitamin D stores early in life, including during fetal 
development (7). It is important that pregnant women have adequate levels of vitamin 
D, since a strong relationship between maternal and fetal vitamin D status has been 
demonstrated in studies of human subjects (27). 
The lack of adequate vitamin D status is currently a public health problem. 
Rickets and vitamin D deficiency are experiencing a resurgence (5, 6), most notably in 
the northern United States (28). This could contribute to racial health disparities, since 
over 40% of African-Americans of reproductive age suffer from hypovitaminosis D (4). 
The two main human sources of vitamin D are sunlight exposure, which converts 
7-dehydrocholesterol in the skin to vitamin D3, and oral intake. Due to the limited 
dietary sources of vitamin D, serum vitamin D levels are primarily determined by 
sunlight exposure. The amount of vitamin D produced by a given amount of exposure is 
modified by skin pigmentation, with darkly-pigmented populations producing 
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significantly less vitamin D than fair-skinned populations after exposure to similar 
conditions (2). 
Existing guidelines recommend that pregnant women receive 200lU of vitamin D 
per day via an oral supplement (3). However, among African-American women who 
take daily supplementation in twice this amount, the rate of hypovitaminosis D is still 
28% (4). The incidence of rickets, a pathology which can develop among children with 
hypovitaminosis D, is increasing, especially among darkly-pigmented populations (5-7). 
Studies are currently underway to determine the optimum supplementation dose of 
vitamin D among pregnant women (Wagner, Hollis, in progress). Once the optimum 
dose is determined, the treatment effect of this intervention will be modified by the 
level of nonadherence among the patient population. The clinical implications of 
nonadherence are numerous and well-recognized (8). 
Serum Assays to Assess Vitamin 0 Status 
In assessing adherence, it is important to consider the characteristics of the 
population under study. The analysis in the attached paper focuses on pregnant 
women. Pregnant females are generally an adherent population, as was demonstrated 
by the success of a recent maternal folate supplementation program(29). 
In order to assess the consistency of adherence to vitamin D supplements over a 
long period of time, the measurable metabolite with the longest half-life should be 
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measured. 2S-hydroxyvitamin D (2S[OH] D) has a 2-3 week half-life, making it ideal for 
this purpose. 
Besides half-life, other important considerations raised previously with regards to 
assessing patient adherence via serum metabolite level include: 
a. other possible sources of the compound in question, 
b. possible factors that could affect the way the body stores and metabolizes the 
compound, and 
c. how to establish an adequate cut-off value that indicates adherence. 
Due to the low levels of vitamin D found even in supplemented food sources, 
2S(OH)D levels are principally determined by supplementation and the exposure to 
Ultraviolet B (UV B) radiation. The time of year that each subject enrolled is therefore 
important to consider in analysis of data, since daily sun exposure and clothing vary 
significantly by season. It is also important to remember that the amount of 2S(OH)O 
that a person produces when presented with a certain amount of UV B exposure is 
significantly modified by skin pigmentation (2). Therefore, initial skin pigmentation is 
also important to consider when analyzing levels of 2S(OH)D after supplementation. 
Finally, BMI and body fat percentage have been found to have an inverse 
relationship with serum levels of vitamin D metabolites in several recent studies (21, 22, 
30). Therefore, initial BMI was also important to consider in the analysis of adherence 
by serum metabolite levels. 
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The most difficult step in a serum assay analysis is the decision to establish a 
threshold serum value, above which subjects would be considered adherent. In this 
case, the foundation of the serum adherence thresholds of 2S-0HD was grounded in the 
Heaney regression model (31). Of note, the predicted serum changes in 2S(OH)D levels 
in the Heaney model were calculated on the basis of dose taken rather than dose 
prescribed. Therefore, they did make an effort to account for nonadherence in the 
study. It is also important to note the lack of available data concerning the effects of a 
given oral supplementation dose of vitamin D3 on the serum 2S(OH)D levels in females 
as opposed to males. The attached analysis used data from a cross-sectional study of a 
population (32) to adjust the predicted serum adherence thresholds rather than a 
controlled trial of supplementation doses. However, we feel that the present study was 
based on the best information currently available. 
Conclusion 
In summary, the measurement of patient adherence is a difficult process due to 
the unique advantages and disadvantages of each method by which it is assessed. 
However, it is worth the effort to use the most accurate method that is feasible given a 
current situation, given the important effects of patient adherence on both research 
studies and clinical practice. 
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Chapter 3 - Methods: 
Study Design 
The study from which the data for this analysis were derived was a large 
randomized, controlled, and double-blinded trial of vitamin D supplements in pregnant 
women. The women had been stratified by race and randomized into three groups, 
each of which received a 400lU, 2000lU, or 4000lU dose of vitamin D3 once daily. 
Women entered the study at or before 12 weeks gestation and continued their 
supplementation throughout pregnancy and the first year postpartum. 
Eligible subjects self-identified as Caucasian, African-American, or 
Hispanic/Latina and carried singleton pregnancies. All subjects were patients at 
obstetric clinics at the Medical University of South Carolina (MUSC, located in 
Charleston, SC, USAL and participated in a monthly study visit as an extension of their 
regular prenatal checkup. They were also asked to return to the clinic three times for 
study visits after the birth of their infants. At each study visit, levels of 25(OH) D and 
vitamin D3 were measured in patient serum. In addition, subjects were asked to bring 
their supplement bottle with them to their monthly visits, containing all unused 
supplements. 
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Note: The above-referenced research protocol was approved by the Medical University 
of South Carolina Institutional Review Board for Human Research. 
Measures 
Outcomes: Outcomes in this study were measured as percent adherence by pill 
count and adherence by serum metabolite levels. These values were determined at 
multiple time points for each patient. 
Percent adherence by pill count 
This was measured at each time point for each subject provided that pill count 
data were available. Subjects were asked to bring their supplement containers, 
containing all unused doses, with them to each monthly study visit. The percentage 
adherence at each time point for each subject was determined by the following formula: 
(# of pills dispensed - # of pills returned) / (# of elapsed days between dispense date and 
return date) 
Two dichotomous variables of adherence by pill count were also created for each 
time point, based on whether the percent adherence by pill count was above the 
threshold levels of 70% and 85%. 
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A summary measure of the mean percent adherence by pill count for each 
subject was cafcuiated by takIng the mean of percent aanefencef(J(31Ivi(((({(J(WfliCfl 
pill count data was available for that subject 
In data analysis, some subjects were evaluated as more than 100% compliant by 
the above formula. This could occur if women returned the pill bottle containing fewer 
doses than were expected given the time interval. Since it is not possible to be more 
than 100% adherent, we assigned each of these subjects a 100% adherence for the 
corresponding time interval and recorded elsewhere in the dataset that these values 
were originally over 100%. 
Adherence by serum metabolite levels 
Adherence by serum metabolite levels was recognized as difficult to define. 
While there is a model in existence which calculates the predicted change in serum 25-
OHD for different doses of vitamin D supplement (31), this model was developed using 
data from men, and its applicability to a population of pregnant females is debatable. 
Therefore, we were faced with the challenge of establishing novel criteria for vitamin 0 
supplement adherence by serum 2S-0HD levels among pregnant females. 
The 2S-0HD level for each patient had been obtained at each monthly visit. In 
general, women have been found to have lower 2S-0HD serum levels than men (20). 
This has been further elucidated by research showing that after adjusting for differences 
in season at enrollment, percent body fat, exercise habits, and age, the vitamin D levels 
of men are approximately 24% greater than those of women in a cross-sectional study 
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(32). While there is no data comparing how women and men respond to identical doses 
of vitamin D3, these studies were thought to provide reasonable expectations of serum 
metabolite-based adherence thresholds. 
According to the Heaney regression model (31), each additional 40 IU of vitamin 
D3 ingested on a daily basis will elevate the circulating 2S-0HD levels by approximately 
0.28 ng/ml in adult males. After calculating the predicted serum 2S-0HD for the doses 
used in this study and decreasing these values by 24% to adjust for gender differences, 
it was determined that values of 10.6 ng/ml and 21.2 ng/ml increases in serum 2S-0HD 
from baseline would be used as thresholds to define subject adherence to doses of 2000 
IU and 4000 IU, respectively. 
Variable Definitions: 
Assigned dose is categorized by the treatment group to which each subject 
belongs. Both subjects and clinicians are blinded to the assigned dose, which is 
one of three options: 4001U, 20001U, or 40001U. 
Maternal race, marital status, and highest education level were determined by 
self-identification on a questionnaire administered at enrollment. 
Maternal age was calculated as self-reported date of birth subtracted from date 
of enrollment. 
Season at enrollment was determined by season (Winter, Spring, Summer, Fall) 
at first visit date. 
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Initial BMI was calculated by trained staff based on each subject's measured 
height and weight at her first visit date. 
Skin pigmentation was determined by the first available measure of skin 
pigmentation in the inner arm as measured by the Smart Probe 400. The median 
value was determined, and a dichotomous variable was created defining women 
as either darker or lighter than the median subject skin pigmentation. 
Confounding Variables: We investigated for the presence of confounding by 
performing bivariate analyses. In these analyses (Table I), dosing groups were shown to 
be well-randomized with respect to race, age, season at enrollment, skin pigmentation, 
marital status, education level, and initial BMI. 
Table 1: Demographic comparison of dosing groups to assess randomization 
~ 
Covariate level 400lU 2000lU 4000lU Chi-square test 
n= 92 n=92 n=87 p-value 
-~~~-- --
Maternal race Black 14 (15%) 21 (22%) 19 (22%) 0.57 
f--- --
latina 42 (46%) 43 (47%) 36 (41%) 
White 36 (38%) 28 (29%) 32 (33%) 
--
Maternal age <20 9 (10%) 0(0%) 7 (8%) 0.12 
1-- -----
20-<25 24 (26%) 29 (32%) 25 (29%) 
25-<30 30(33%) 27 (29%) 27 (31%) 
30+ 29 (32%) 36 (39%) 28 (32%) 
Season Spring 28 (30%) 29 (32%) 29 (33%) 0.94 
Summer 21 (23%) 24 (26%) 20 (23%) 
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Table l--continued 
Fall 20 (22%) 22 (24%) 17 (20%) 
Winter 23 (25%) 17 (18%) 21 (24%) 
--
Skin Lighter than 37 (57%) 32 (43%) 37 (55%) 0.21 
pigmentation median 
t--------
Darker than 28 (43%) 42 (57%) 30 (45%) 
median 
Marital status Married 53 (58%) 49 (53%) 49 (57%) 0.81 
other 39 (42%) 43 (47%) 37 (43%) 
--
Maternal < high school 18 (20%) 19 (21%) 13 (15%) 0.51 
I 
Education 
HS grad 14 (16%) 14 (15%) 14 (17%) 
Some college/ AA 24 (27%) 34 (37%) 31 (37%) 
Bachelors 12 (14%) 5 (5%) 12 (14%) 
Postgraduate 20 (23%) 19 (21%) 14(17%) 
education 
BMI Median (IQR) 25.2 (8) 25.8 (8) 25.2 (9) 0.6* 
---
*p-value of Kruskal-Wallis test (SMI followed non-normal distribution) 
Statistical Analyses 
First, a series of pairwise comparisons was performed in order to assess any 
demographic or baseline variable differences between treatment groups (Table 1). For 
all analyses in this study, 0.05 was the significance level threshold. 
The data were also examined for bivariate associations of adherence by serum 
measures with demographic variables. Graphical representations of data were created 
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and examined for trends in adherence by the serum metabolite measures as categorized 
















































Visit 2 Visit 3 Visit 4 Visit 5 
Figure l--Adherence by Age over 5 Time Intervals 
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Visit 6 
Adherence by Race over 5 Time Intervals 
80 
o African American 
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* Note : 100% was used as a maximum value for adherence; see section on limitations 
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Adherence by Initial 8MI over 5 Time Intervals 
0<18.5 
t:l 18.5 - <25 
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Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 
Figure 5--Adherence by Initial BMI over 5 Time Intervals 
Data was compiled to examine trends in the change in 25-0HD from baseline to 
each visit in adherent and nonadherent groups as classified by the serum 25-0HD 
thresholds, as well as two standards of adherence as measured by pill count, 70% and 
85% (Table 2). Graphical representations of these data were also created (Figures 6-7). 
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Table 2: Change in 250HD from baseline of adherent/nonadherent subjects over 5 
time intervals by 3 definitions of adherence 
Visit 
number Definition 
mean change 250HD from 
in baseline to steady state 
2000lU 4000lU 
Visit 2 Serum adherent (n= 80, 43%) 18.3 25.3 
nonadherent (n= 107) 13.2 20.3 
Difference 5.1 5.0 
Pill 
Count adherent (n= 127, 68%) 11.8 19.2 
700/0 nonadherent (n= 60) 10.1 12.8 
Diffbl ~llv~ 1.7 6.4 
Pill 
Count adherent (n= 95, 51 %) 11.3 18.2 
85% nonadherent (n= 92) 11.1 16.4 
Difference 0.2 1.8 
Visit 3 Serum adherent (n= 92, 50%) 23 29 
nonadherent (n 93) 12.8 20 
Diffbl ~llce 10.2 9.0 
Pill 
,Count ddh~l~fll (n 132 71 %) 12.7 21.9 
70% nonadherent (n 53) 13.4 18.9 
Difference -0.7 3.0 
Pill 
Count ddh~I~11l (n 109 59%) 12.7 22.6 
85% IlVlldUII~1 ~lIl (n 76) 13.1 18.9 
Difference -0.4 3.7 
f_V __ ' ,il_S.;"i .. t_4' ___ I_S_;_,e_~r.U_lm~ __ ~_a_d_h_er_e~nt~(Q~_1~0~2~15_8._%~,)~~_~ ____ 3_1_.6~ __ ~ ___ 3_4_,1_4 
nonadherent (n=73) 13.7 21.5 
Difference 17.9 12.6 
Pill 
Count adherent (n= 117,67%) 17.0 22.5 
700/0 nonadherent (n= 57) 14.1 19.8 
Difference 2.9 2.7 
Pill 
Count aJr.vlvlIl (n 98, 56%) 17.5 22.4 
85% nonadherent (n= 76) 14.0 20.7 
Difference 3.5 1.7 
Visit 5 Serum ddhl;;lvl It (n 97 64%) 19 27.1 
nonadherent(n :54) 9.6 15.3 
Difference 9.4 11.8 
Pill 
Count adherent (n 95, 72%) 16.5 27.5 
70% nonadherent (n= 37) 15.4 20.0 
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Table 2--continued 
Difference 1.1 7.5 
Pill 
Count adherent (n= 79, 60%) 16.7 27.9 
85% nonadherent (n= 53) 15.5 21 .5 
Difference 1.2 6.4 
Visit 6 Serum adherent (n= 70, 48%) 22.9 31 
nonadherent (n= 35) 10.4 16.6 
Difference 12.5 14.4 
Pill 
Count adherent (n= 0) * * 
70% nonadherent (n= 1) * * 
Difference * * 
Pill 
Count adherent (n= 0) * * 
85% nonadherent (n= 1) * * 
Difference * * 

























Change in Serum 25-0HD from Baseline over 5 Time Intervals by 3 Definitions of 
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~
:-;-=-S~~~~ cutoff~ 
.. .. . 70% Pill Count 
- - 85% Pill Count 














L· ·~ lII! ••••••••••••• • • ••• ~:,,: ~ .. .. ~ ~ . - --'.-'- >-.......- 7.~ --.---- - ----,-- --.-----,--
Visit 2 villi 3 Visit 4 Visit 5 Visit 6 
Figure G--Change in Serum 2S-0HD from Baseline over 5 Time Intervals by 3 Definitions of 
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Figure 7--Changes in Serum 2S-0HD from Baseline over 5 Time Intervals by 3 Definitions of 
Adherence--4000 IU Dose 
A series of 5 multivariate logistic regression models were created to examine 
whether mean percent adherence by pill count was significantly associated with being 
adherent by serum 25(OH)D threshold while controlling for race, age, initial 8MI and 
season at enrollment (Table 3). 
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Table 3: Odds ratios of the association of pill count with attainment of threshold 
serum values when controlling for possible c;onfounding variables 
Variable; OR; 
95%CI; p-value Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 
Mean Pill Count 
Adherence 1.1 1.0 0.9 1.0 1.0 
95% CI 0.9-1 .3 0.8-1 .3 0.6-1.2 0.7-1.3 0.7-1.4 




overall p-value 0.17 0.31 0.11 0.29 0.95 
Black v. White 2.9 2.5 2.5 3.3 1.4 
95% CI 0.9-9.0 0.8-8.1 0.6-9.6 0.7-15.1 0.2-9.9 
P-value 0.07 0.13 0.19 0.12 0.75 
Hispanic v. White 1.4 1.5 3.7 2 1.2 
95% CI 0.5-3.7 0.6-4.0 1.1-12.4 0.6-6 .2 0.2-5.8 
P-value 0.52 0.39 0.04 0.25 0.85 
.; '.' "i .'. /;. \, .. " .. , 
""., ,., ,< .,.' .S .p' ". ' .. ·." .. ··v '/ ,. !.; 
Dose (1 v. 2) 1.2 0.8 2.1 0.6 1.0 
95% CI 0.5-2.6 0.4-1 .8 0.9-5.2 0.2-1.6 0.3-3.0 
P-value 0.69 0.58 0.10 0.34 0.97 
Mom age in Yrs 1.0 1.1 1.0 1.1 1.1 
95% CI 0.9-1.1 0.99-1 .2 0.9-1.1 0.99-1.2 0.9-1.2 
P-value 0.81 0.08 0.48 0.07 0.27 
; . 
. . i·Y.,' ..... "'/\'" . ". .. . 
Season 
overall p-value 0.92 0.70 0.89 0.74 0.58 
Fall v. Winter 1.1 1.4 0.7 0.7 1.2 
95% CI 0.3-4.1 0.4-4.6 0.2-2 .9 0.2-2.8 0:2-6.4 
P-value 0.89 0.61 0.66 0.58 0.83 
Spring v. Winter 1.10 0.70 1.20 1.00 1.6 
95% CI 0.4-3.1 0.3-2.2 0.3-4.1 0.3-3.7 0.3-8.6 
P-value 0.93 0.60 0.79 0.97 0.57 
Summer v. 
Winter 1.4 0.8 1.0 0.6 0.6 
95% CI 0.5-4.2 0.3-2.5 0.3-3.9 0.1-2.2 0.1-2.9 




, .' d,·:{·i;~I::;;:;;\;t1i , ~:;::i;~r,.;t ..... ,,; , Xc Ai .,0" Ii . 
8MI 1.0 1.0 1.0 1.0 1.0 
95% CI 0.9-1 .03 0.96-1.02 0.9-1 .03 0.97-1.1 0.96-1.1 
P-value 0.47 0.59 0.22 0.41 0.48 
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Chapter 4 - Results 
The three dosing groups included in this analysis were an active control group 
that was given supplements containing 400 IU of vitamin D3 (twice the current 
Recommended Daily Allowance)} a group taking 2000 lU, and a third group taking 4000 
IU. Subjects in all groups were instructed to take one supplement once daily. A 
summary of pairwise comparisons of the demographics of dosing groups (Table i), 
reveals that subjects in all dosing groups were not significantly different with respect to 
race, age} season at enrollment, initial inner arm skin pigmentation measurement, 
marital status, education level, or initial BMI. 
The data were first examined for bivariate associations of compliance by serum 
2S(OH)D level with demographic variables. Graphical representations of data show 
percent of subjects reaching adherence by the serum metabolite adherence definitions 
as categorized by age, race, dosing group, initial BMI, and season of enrollment. While 
trends in age show a lower level of adherence in the youngest age group, no other 
consistent trends of adherence and age were evident (Figure 1). Race, season at 
enrollment and initial BMI showed no consistent trends (Figures 2, 4-5). While the data 
show a trend towards higher adherence by serum 2S-0HD among the 2000 IU dosing 
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group as opposed to the 4000 IU dosing group, this only achieves the level of 
significance at visit 4 (Figure 3). 
In terms of percentage adherence at each time point, the 70% adherence by pill 
count was the most generous standard, with percent adherence ranging from 68% to 
72% of subjects at each time point. The 85% adherence by pill count standard and the 
established serum 25-0HD thresholds were comparable in the percentage of subjects 
classified as adherent, with ranges from 51-60% and 43-64%, respectively (Table 2). 
However, upon examining the mean difference in change in 250HD level between 
adherent and nonadherent subjects for these standards, it is evident that the subjects 
classified as adherent under these two standards were very different. The mean change 
in 25(OH)D from baseline was greater for the group deemed adherent by serum 
standards than for the group classified as adherent by the 85% pill count standard at 
every time point. This was also represented graphically (Figures 6-7). 
Finally, a series of 5 multivariate logistic regression models were created to 
examine whether mean percent adherence by pill count was significantly associated 
with the thresholds of adherence by serum 25(OH) 0 when controlling for race, dose, 
age, season at enrollment, and initial BMI. The analysis revealed that mean percentage 
of adherence by pill count was not a significant predictor of adherence by serum 25-
OHD at any time point. Odds ratios ranged from 0.9 to 1.1, and a significance level of 
0.05 was not reached at any time point (Table 3). 
36 
Chapter 5- Discussion 
The importance of adherence to medication has been recognized in clinical trials 
and daily clinical practice alike. In order to properly evaluate the effects of medications, 
it is vital to determine whether they are taken as prescribed. The most frequent 
manner to evaluate adherence has been pill count, which offers advantages such as low 
cost and simplicity of collection and calculation, but yet has the disadvantages of 
frequently missing data and possible manipulation by subjects (11). In this trial, we 
sought to determine whether there was a significant association between adherence to 
vitamin D supplementation as measured by pill count and assessment of adherence 
based upon serum levels of vitamin D metabolites in a pregnant population. 
The results of the present study could offer a new perspective on the 
determination of efficacy in clinical research. Currently, the efficacy of medications and 
supplements is determined primarily via randomized controlled clinical trials, in which 
subject adherence is assumed or measured via pill count. If there were an objective 
laboratory value by which adherence could more accurately be determined, studies 
could include the most adherent patients in the analysis to get a clearer picture of 
efficacy without the dilution of the treatment effect by nonadherent patients. 
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According to the multivariate logistic regression analysis performed there was 
not a significant association between adherence as defined by serum metabolite level 
and mean percent pill count adherence for any time point. This confirms previous 
studies which showed that pill count data are prone to errors (11). However, this 
analysis is unique in that it utilizes the pharmacokinetics of vitamin 0 metabolism to 
predict adherence, and the data are then compared to pill counts. 
Another important finding of the analysis was a lack of a significant association 
between race and adherence. In a previous study of prenatal supplementation, non-
Hispanic blacks were found to be less adherent than non-Hispanic whites (9). The lack 
of significance found in the present analysis could be due to the inclusion of Latina 
subjects, or could suggest that pill count data may overestimate the disparities of 
adherence among ethnic groups. 
The study also offers an objective measure of adherence for vitamin 03 -
containing supplements in women. Objective measures of known metabolites could be 
used more frequently in the clinic to monitor patient adherence to this and other 
prescribed regimens, much as HbA1C levels are currently used to monitor long-term 
blood glucose control in diabetic patients. 
Strengths of this study include the collection of both pill count-based and serum 
metabolite-based adherence data at multiple time pOints. The study is strengthened by 
the consistency of findings across mUltiple time points. In addition, the subject 
population in this study was composed exclusively of pregnant women, which are 
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generally an adherent population, as was demonstrated by the success of a recent 
maternal folate supplementation program(29). 
A final strength of this study was the foundation of the serum adherence 
thresholds of 2S-0HD in the Heaney regression model (31). Of note, the predicted 
serum changes in 25(OH)D levels in this model were calculated on the basis of dose 
taken rather than dose prescribed. Therefore, they did make an effort to account for 
nonadherence in the study. However, the dose taken was based on patient pill count, 
so given the overestimation of adherence by pill count, there could still be some dilution 
of treatment effect in this model. 
A limitation of the study was missing pill count data, which limited the sample 
size. In fact, 10% of the original subject population was eliminated from this analysis 
because the subjects did not have a single time point at which pill count data were 
available. The majority of patients did not have pill count data for all time points, 
meaning that their general level of adherence was essentially imputed from time points 
at which data were available. This may not be accurate, as an interim lack of adherence 
could have contributed to not returning the pill bottle at certain time points. There 
could also be unknown third factors, such as a more hectic schedule during certain 
months, which could both affect adherence and the likelihood of remembering to bring 
the pill bottle to the next appointment. The lack of data is a persistent problem in pill 
count adherence analyses, and one which can hopefully be alleviated in the future by 
changing the way adherence is measured in clinical trials. 
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Another limitation of this study was the lack of available data concerning the 
effects of a given oral supplementation dose of vitamin 0 3 on the serum 25(OH)0 levels 
in females as opposed to males. The study used to adjust the predicted serum 
adherence thresholds was a cross-sectional study of a population(32), not a controlled 
trial of supplementation doses. Therefore, the gender differences in 25(OH)0 levels 
could have been due to confounding factors. However, we feel that the present study 
was based on the best information currently available. 
A final limitation of the study was that using the formula for percent adherence 
by pill count, some subjects were found to be more than 100% adherent. This occurred 
when a subject returned a pill bottle containing less pills than anticipated given the time 
interval since the last visit. This raises a problem because taking more medication than 
prescribed is a form of nonadherence. It cannot be known whether more doses than 
prescribed were taken, or if these were spilled or consumed by other individuals. To 
deal with this problem, we assigned each of these subjects a 100% adherence for the 
corresponding time interval and recorded elsewhere in the dataset that these values 
were originally over 100%. Adherence by pill count therefore refers to returning the 
number or pills expected given the time interval or less. We believe that this was 
justified because there was also no upper limit on serum 25(OH)D levels, so subjects 
taking more supplement than prescribed would have been classified as adherent by this 
measure as well. 
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In conclusion, this study raises important questions about the utility of pill count 
in assessment of adherence in both clinical research and daily medical practice. 
Avenues for further research include the study of serum 25(OH)D levels in males and 
females taking an identical oral dose of vitamin D3 and other, more innovative and 
reliable measures of subject adherence to prescribed regimens. 
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